Physician profile
Michael L Malone
NPI 1164508263
$2,925.67
in general payments reported to CMS, 2019-2025
20 companies · $306 in 2025
The $306 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $403 · 2020: $274 · 2021: $451 · 2022: $541 · 2023: $377 · 2024: $573 · 2025: $306.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,256.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,255.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $749.38 | 2019-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $314.19 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $281.30 | 2022-2025 | |
| Pfizer INC. | $198.67 | 2019-2025 | |
| Xeris Pharmaceuticals, INC. | $168.38 | 2022-2025 | Gvoke Hypopen |
| Exact Sciences Corporation | $164.53 | 2023-2025 | Cologuard Collection Kit |
| Si-Bone, INC. | $145.93 | 2022 | |
| Amgen INC. | $136.36 | 2019-2025 | Repatha, Evenity, Otezla |
| Preventric Diagnostics, INC. | $133.33 | 2021 | |
| Janssen Pharmaceuticals, INC | $116.84 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $112.32 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.62 | 2020-2023 | Jardiance |
| Glaxosmithkline, LLC. | $69.42 | 2020-2023 | Shingrix, Arexvy |
| Gilead Sciences, INC. | $47.99 | 2019 | |
| Sunovion Pharmaceuticals INC. | $45.86 | 2020-2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $40.33 | 2023-2024 | Eliquis |
| Novo Nordisk INC | $36.18 | 2025 | Ozempic |
| Seqirus USA INC | $33.60 | 2019 | |
| Sanofi-Aventis U.S. LLC | $28.20 | 2019-2022 | |
| Dexcom, INC. | $22.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Malone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.